Genor Biopharma Holdings Ltd. engages in the development and commercialization of oncology and autoimmune drugs. The company is headquartered in Shanghai, Shanghai and currently employs 17 full-time employees. The company went IPO on 2020-10-07. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241), Vancocin, Ceclor and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The firm mainly conducts its business in the domestic market.